On Super Bowl Sunday, many tuning into the big game saw a controversial ad from the telehealth company Hims & Hers. The ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past several ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Shares of fellow Danish obesity drug maker Zealand Pharma also tracked higher, last up 4.7%, while Zepbound-maker Eli Lilly dipped in ... showed average weight loss of 13.1% after 12 weeks.